Thalidomide as a Potential Treatment for Scleromyxedema

Archives of Dermatology

Volumn 140, Issue 3, 2004, Pages 277-280

  Caradonna, Stephanie ^a   Jacobe, Heidi ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADULT; AMENORRHEA; ARTICLE; CARDIOTOXICITY; CASE REPORT; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; ELECTROMYOGRAPHY; FEMALE; HUMAN; LIVER FUNCTION TEST; NEUROTOXICITY; PRIORITY JOURNAL; SCLEROMYXEDEMA; SENSORY NEUROPATHY; SIDE EFFECT; SKIN BIOPSY; SKINFOLD THICKNESS; TERATOGENICITY;

ADMINISTRATION, ORAL; ADULT; DIAGNOSIS, DIFFERENTIAL; FACIAL DERMATOSES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHENOID ERUPTIONS; LOWER EXTREMITY; MYXEDEMA; THALIDOMIDE; UPPER EXTREMITY;

EID: 1542724642     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.3.277     Document Type: Article

References (44)

1. Dubreuilh W. Fibromes miliaires folliculaires: sclerodemie consecutive. Ann Dermatol Syph. 1906;37:569-572.
2. Reitmann K. Uber eine eigenartige, der sklerodermie nahestehende affektion. Arch Dermatol Syph. 1908;92:417-424.
3. Montgomery H, Underwood LJ. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol. 1953;20:213-236.
4. Gottron HA. Skleromyxodem (eine eigenartige erscheinung Form von Myxothesaurodermie). Arch Dermatol Syph (Berl). 1954;199:71-91.
5. Gabriel SE, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore). 1988;67:58-65.
6. Dinnen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33:37-43.
7. McCuiston CH, Schoch EP Jr. Autopsy findings in lichen myxedematosus. Arch Dermatol. 1956;74:259-262.
8. Kantor GR, Bergfeld WF, Katzin WE. Scleromyxedema associated with scleroderma renal disease and acute psoriasis. J Am Acad Dermatol. 1986;14:879-888.
9. Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:289-294.
10. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science. 1978;199:545-547.
11. Chandra JJ. Scleromyxedema. Cutis. 1979;24:549-552.
12. Ferrarini M, Helfrich DJ, Walker ER, Medsger TA Jr, Whiteside TL. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol. 1989;16:837-841.
13. Kaufman D, Truha AP, Roenigk HH Jr. Scleromyxedema: systemic manifestations and cosmetic improvement with dermabrasion. Cutis. 1987;39:321-324.
14. Farr PM, Ive FA. PUVA treatment of scleromyxoedema. Br J Dermatol. 1984;110:347-350.
15. Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988;19:469-477.
16. Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol. 1991;24:854-857.
17. Rudner EJ, Mehregan A, Pinkus H. Scleromyxedema: a variant of Lichen myxedematosus. Arch Dermatol. 1966;93:3-12.
18. Perry HO, Montgomery H, Stickriey JM. Further observations on lichen myxedematosus. Ann Intern Med. 1960;53:955-969.
19. Cohen AM, Hodar E, David M, Mittelman M, Gal R, Stern R. Beneficial effect of granulocyte-colony stimulating factor in scleromyxedema associated with severe idiopathic neutropenia. Br J Dermatol. 1996;135:626-629.
20. MacFarlane AW, Davenport A, Verbov JL, Goldsmith HJ. Scleromyxoedema: successful treatment with plasma exchange and immunosuppression. Br J Dermatol. 1987;117:653-657.
21. Lowe NJ, Dufton PA, Hunter RD, Vickers CF. Electron-beam treatment of scleromyxoedema. Br J Dermatol. 1982;106:449-453.
22. Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000;43:403-408.
23. Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol. 1999;40:303-307.
24. Berkson M, Lazarus GS, Uberti-Benz M, Rook AH. Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol. 1991;25:724.
25. Feldman P, Shapiro L, Pick AI, Slatkin MH. Scleromyxedema: a dramatic response to melphalan. Arch Dermatol. 1969;99:51-56.
26. Harris RB, Perry HO, Kyle RA, Winkelmann RK. Treatment of scleromyxedema with melphalan. Arch Dermatol. 1979;115:295-299.
27. Bata-Csorgo Z, Husz S, Foldes M, et al. Scleromyxedema. J Am Acad Dermatol. 1999;41:343-346.
28. Davis LS, Sanal S, Sangueza OP. Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol. 1996;35:288-290.
29. Howsden SM, Herndon JH Jr, Freeman RG. Lich myxedematosus: a dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol. 1975;111:1325-1330.
30. Jessen RT, Straight M, Becker LE. Lichen myxedematosus: treatment with cyclophosphamide. Int J Dermatol. 1978;17:833-839.
31. Verity MA, Toop J, McAdam LP, Pearson CM. Scleromyxedema myopathy: histochemical and electron microscopic observations. Am J Clin Pathol. 1978;69:446-451.
32. McAdam LP, Pearson CM, Pitts WH, Sadoff L, Verity MA. Papular mucinosis with myopathy, arthritis, and eosinophilia: a histopathologic study. Arthritis Rheum. 1977;20:989-996.
33. Wieder JM, Barton KL, Baron JM, Soltani K. Lichen myxedematosus treated with chlorambucil. J Dermatol Surg Oncol. 1993;19:475-476.
34. Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients: the revival of an old drug. Br J Haematol. 2000;108:391-393.
35. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89-96.
36. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75:897-901.
37. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
38. Moller DR, Wysocka M, Greenlee BM, et al. Inhibition of IL-12 production by thalidomide. J Immunol. 1997;159:5157-5161.
39. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160-167.
40. Hastings RC. Kellersberger Memorial Lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues. Ethiop Med J. 1980;18:65-71.
41. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res. 1980;269:275-280.
42. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol. 1984;11:814-819.
43. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
44. Verheul HM, Panigrahy D, Yuan J, D'Amato RJ. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer. 1999;79:114-118.